Prevention and therapy of bone loss and fractures in sufferers present process a hematopoietic stem cell transplant: a scientific evaluation and meta-analysis.
Bone Marrow Transplant. 2017 Might;52(5):663-670
Authors: Pundole X, Cheema HI, Petitto GS, Lopez-Olivo MA, Suarez-Almazor ME, Lu H
The simplest technique to stop and deal with bone loss following hematopoietic stem cell transplantation (HSCT) stays unsure. We performed a complete search in 4 digital databases till August 2015. We retrieved articles describing sufferers with bone loss or fractures who acquired HSCT. Managed trials, with a follow-up interval of a minimum of 12 months, had been included. Twelve research (19 publications) met our inclusion standards. A complete of 643 members underwent HSCT (85.7% allogeneic HSCT). There was a statistically important decrease imply bone mineral density (g/cm2) proportion change of the lumbar backbone (imply distinction (MD) 7.eight, 95% confidence interval (CI) 5.6-10.zero) and femoral neck (MD 6.7, 95% CI 5.6-7.9) within the bisphosphonate remedy group in contrast with the management group with no bisphosphonate remedy at 12 months. In a subgroup evaluation, seven completely different comparability teams had been evaluated. The speed of fractures or X-ray findings of subclinical vertebral fractures was comparable between teams. Bisphosphonates are promising within the prevention and therapy of bone loss following HSCT. Extra analysis is required to find out whether or not they cut back long-term fracture threat.
PMID: 28112742 [PubMed – indexed for MEDLINE]